Madrigal Pharmaceuticals

Madrigal Pharmaceuticals is a biopharmaceutical company developing therapeutics for the treatment of cardiovascular-metabolic diseases.

Funding reportedLast round: Post ipo equity

BiopharmaConshohocken, United States

What company datasets say Madrigal Pharmaceuticals raised

Funding, as reported

Reported in all$1.6Bin dollars

Rounds8

Last roundPost ipo equity

Last round dateMar 2024

Investors listed2

From the SEC filings it signed: 2 on the team.

On the board, as filediDavid R. MilliganFred B. CravesKeith R. GollustKenneth M. BateRebecca A. TaubRichard S. Levy

Investors who name them

Each firm lists Madrigal Pharmaceuticals on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.

Startups like it

Add your raise, your deck and your story, and put Madrigal Pharmaceuticals in front of investors. Or tell us what we have wrong.